Category Archives: Cell Therapy

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Cell Therapy And Tissue Engineering Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Cell Therapy And Tissue Engineering Market Overview

The Cell Therapy And Tissue Engineering Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Cell Therapy And Tissue Engineering market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Cell Therapy And Tissue Engineering Market: Competitive Landscape

The Cell Therapy And Tissue Engineering Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Cell Therapy And Tissue Engineering Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Cell Therapy And Tissue Engineering Market Segment by Type:

Cell Therapy And Tissue Engineering Market Segment by Application:

Cell Therapy And Tissue Engineering Market Regional overview:

In the report, experts analyze and forecast the Cell Therapy And Tissue Engineering market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Cell Therapy And Tissue Engineering Market Report:

Outlook analysis of the Cell Therapy And Tissue Engineering market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Cell Therapy And Tissue Engineering market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Read the original:
Cell Therapy And Tissue Engineering Market Size, Analysis, Growth, Trends, Outlook And Forecast By 2027 - The Haitian-Caribbean News Network

The latest market intelligence study, called Global Cell Therapy Market Forecast to 2027, jots down some of the most prominent growth potentials of the global Cell Therapy market. The report is primarily targeted at the industry stakeholders looking to capitalize on this reports contents to make improved business decisions. The report is further intended to help the readers gain vital insights into the global market, particularly the prevailing growth opportunities and competitive scenario. The insightful data & information provided by this report are gathered from various primary and secondary sources.

Request a sample copy of this report @https://www.reportsanddata.com/sample-enquiry-form/3269

Competitive Terrain:

The global Cell Therapy market witnesses the significant presence of a large number of companies performing consistently to achieve optimal market growth. The current market standing of these companies, their past performances, the demand & supply graphs, sales network, production & consumption patterns, and distribution channels have been extensively discussed in this report. Furthermore, the report points out the effective business approaches undertaken by the market players to enhance their product portfolios and prosper considerably.

Market segments by Top Manufacturers:

JCR Pharmaceuticals Co. Ltd., Fibrocell Science, Inc., Kolon TissueGene, Inc., Osiris Therapeutics, Inc., PHARMICELL Co., Ltd., MEDIPOST, Stemedica Cell Technologies, Inc., Cells for Cells, Vericel Corporation, and ANTEROGEN Co., Ltd., have been profiled in the report. They are the major manufacturers of the product.

Global Cell Therapy Market report COVID-19 Impact Assessment:

Reports and Datas latest report sums up the significant changes in the global business sector that followed the COVID-19 outbreak. The pandemic has also had an enormous impact on the global Cell Therapy market, disrupting the market dynamics and trends. The global health crisis has gravely affected the Cell Therapy industry, disrupting the global supply chains and bringing about volatility in prices and product demand. However, industry experts believe that the global Cell Therapy market will regain traction in the post-COVID scenario. The report further offers a preliminary and a future assessment of the pandemics impact on this lucrative business space.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.reportsanddata.com/discount-enquiry-form/3269

Therapy Type Outlook (Revenue, USD Billion; 2017-2027)Allogenic Stem Cell TherapyAutologous Stem Cell Therapy

Therapeutic Area Outlook (Revenue, USD Billion; 2017-2027)MalignanciesAutoimmune DisordersMusculoskeletal DisordersDermatologyOthers

Cell Type Outlook (Revenue, USD Billion; 2017-2027)Stem CellsNon-Stem Cells

End-User Outlook (Revenue, USD Billion; 2017-2027)Hospitals & ClinicsAcademic & Research Institutes

Browse the full report description, along with the ToCs and List of Facts and Figures @ https://www.reportsanddata.com/report-detail/cell-therapy-market

Geographical Segmentation:

The report essentially evaluates the significant presence of the global Cell Therapy market across the worlds major regions. The global Cell Therapy market has been categorized into several key geographical regions. North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa are the leading Cell Therapy market regions. In this section of the report, the authors have examined the market share, market size, revenue contribution, sales network, distribution channels, and numerous other aspects of each geographical segment.

The report also provides an extensive analysis of the key market elements, such as drivers, constraints, opportunities, limitations, threats, and micro and macro-economic factors. The exhaustive SWOT analysis, Porters Five Forces analysis, feasibility analysis, and investment return analysis included in the report are intended to help the reader tactfully formulate business growth strategies. Strategic recommendations for the established market players assist them in fortifying their financial positions in the market.

To get a customized sample of the report, click on the link mentioned alongside @ https://www.reportsanddata.com/sample-enquiry-form/3269

Thank you for reading our report. For further information regarding the report or to get a customized copy of it, please connect with us. We will make sure you receive a report perfectly tailored to your needs.

Read the original here:
Cell Therapy Market Growth and Current Status of Industry Surveyed in New Research Report | (2020-2027) - Murphy's Hockey Law

WORCESTER, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will host a key opinion leader (KOL) call on MB-106 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma on Wednesday, December 9, 2020, at 1:00 p.m. EST.

The call will feature presentations by KOLs Mazyar Shadman, M.D., M.P.H., Fred Hutchinson Cancer Research Center (Fred Hutch), and Brian Till, M.D., Fred Hutch, who will discuss the interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma that the company is developing in collaboration with Fred Hutch. Data from this study have been selected for a poster presentation at the 62nd American Society of Hematology Annual Meeting.

During the call, Drs. Shadman and Till will also discuss the modified cell manufacturing process that was co-developed by Fred Hutch and Mustang Bio, as well as the correlative science observed in the study to date. The Mustang team will then give a corporate update on its pipeline and future plans. Following the formal presentations, the Mustang team, along with Drs. Till and Shadman, will be available for questions.

To register for the call, please click here.

About Dr. ShadmanMazyar Shadman, M.D., M.P.H., is an associate professor at the University of Washington (UW) and Fred Hutch. He is a hematologic malignancies expert who specializes in treating patients with lymphoma / chronic lymphocytic leukemia (CLL). He is involved in clinical trials using novel therapeutic agents, immunotherapy (CAR T cell), and stem cell transplant for treatment of lymphoid malignancies with a focus on CLL. He also studies the clinical outcomes of patients using institutional and collaborative retrospective cohort studies. Dr. Shadman received his M.D. from Tehran University in Iran. He finished internal medicine internship and residency training at the Cleveland Clinic in Cleveland, Ohio. He completed his training in hematology and medical oncology fellowships at UW and Fred Hutch. Dr. Shadman also earned an M.P.H. degree from UW and was a fellow for National Cancer Institutes cancer research training program at Fred Hutch, where he studies cancer epidemiology.

About Dr. TillBrian Till, M.D., is an Associate Professor in the Clinical Research Division of Fred Hutch and Department of Medicine at UW. His laboratory focuses on developing chimeric antigen receptor (CAR)-based immunotherapies for non-Hodgkin lymphoma and understanding why CAR T cell therapies work for some patients but not for others. He led the first published clinical trial testing CAR T cells as a treatment for lymphoma patients. Dr. Till also has a clinical practice treating patients with lymphoma and attends on the stem cell transplantation and immunotherapy services at the Seattle Cancer Care Alliance.

About Mustang BioMustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (SEC). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit http://www.mustangbio.com.

ForwardLooking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contacts:Jaclyn Jaffe and William BegienMustang Bio, Inc.(781) 652-4500ir@mustangbio.com

Investor Relations Contact:Daniel FerryLifeSci Advisors, LLC(617) 430-7576daniel@lifesciadvisors.com

Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com

Go here to read the rest:
Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - GlobeNewswire

SAN CARLOS, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA] today announced that the Companys proprietary Helix Biotherapeutic Delivery System (the Helix System) demonstrated the best safety profile among clinical transendocardial catheter injection systems used for cardiac cell therapy delivery in an in-press corrected proof published in the journal, Cardiovascular Revascularization Medicine. The Helix System is being used in the pivotal Phase III CardiAMP Heart Failure Trial currently enrolling nationwide for infusion of BioCardias CardiAMP cell therapy to the myocardium.

The study, which can be accessed here, analyzed clinical trials encompassing 1,789 patients that underwent transendocardial injections using either a helical needle (BioCardias Helix System), or one of three other clinical use designs developed by BioCardia competitors: an electro-anatomically tracked straight needle, a straight needle without tracking elements, or a curved needle. The paper, titled Clinical safety profile of transendocardial catheter injection systems: a plea for uniform reporting,1 was authored by Amish N. Raval, MD, of the University of Wisconsin and Carl J. Pepine, MD, of the University of Florida.

The article reported the combined transendocardial injection-associated serious adverse event (SAE) rate was 3.4% across all four catheters, with the Helix System demonstrating the lowest SAE rate of only 1.1%. The next-closest delivery system had three times as many reported adverse events as the Helix System, with one system having 8.3 times as many adverse events as the Helix System.

In the paper, the authors concluded, the helical needle designed catheter is associated with a particularly low reported rate of death, myocardial infarction, stroke, cardiac perforation causing death or requiring surgical or percutaneous evacuation, serious arrhythmia, and vascular complications.

This rigorous, independent review of the scientific literature follows earlier data showing that Helix has the lowest risk to patients2 and most efficient cell delivery3 compared to other leading delivery routes evaluated. Having the safest and highest performance delivery platform enhances the probability that our clinical cell therapy programs will become valuable therapies for millions of patients suffering from cardiac disease, said BioCardia Chief Executive Officer Peter Altman.

About BioCardiaBioCardia, Inc., headquartered in San Carlos, California, is developing autologous and allogenic cell-based therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the Companys biotherapeutic product candidates in clinical development. The Company has also developed a portfolio of approved enabling products that optimize delivery of its cell therapies.

Forward Looking Statements This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the safety and efficiency of cell delivery using the Companys delivery systems.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in our documents filed with the SEC, including our recent filings on Form 8-K, Form 10-K and Form 10-Q, particularly any statements under the caption entitled Risk Factors therein. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. References

Media Contact: Michelle McAdam, Chronic Communications, Inc.Email:michelle@chronic-comm.comPhone: 310-902-1274

Investor Contact: David McClung, Chief Financial OfficerEmail:investors@BioCardia.comPhone: 650-226-0120

Original post:
BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used in CardiAMP Phase III Heart Failure Trial Has Fewest Adverse...

A study published in Blood Advances observed that extranodal involvement and lymphoma burden are risk factors for early progression at the time of diagnosis and time of treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) being treated with chimeric antigen receptor (CAR) T-cell therapy.

Researchers sought to identify factors that may predict CAR T-cell failure, particularly early progression, within the first month after infusion. The study included 116 patients (median age, 60.7 years) with relapsed/refractory DLBCL who were analyzed at the time of decision to use commercial CAR T-cell treatment and at the time of treatment. Patients were treated at five French Lymphoma Study Association centers between June 2018 and January 2020.

Median time from decision to apheresis was nine days (range, 5.5-16.5 days), and the median time between apheresis and infusion was 40 days (range, 36-45 days). After a median follow-up of 8.2 months, 55 patients relapsed; 49% of relapses (n=27) occurred within the first month after infusion.

The estimated 12-month progression-free survival (PFS) and overall survival (OS) were 47.2% (95% confidence interval [CI], 38.0-58.6) and 67.0% (95% CI, 57-79), respectively.

Univariate analyses for PFS and OS found that the following characteristics predicted CAR T-cell failure: Eastern Cooperative Oncology Group performance status score of 2, stage III/IV disease, two or more extranodal sites, elevated lactate dehydrogenase (LDH), increased C-reactive protein (CRP), high International Prognostic Index at time of decision and time of treatment, as well as increased CRP, bulky mass, and high total metabolic tumor volume at time of treatment.

Multivariate analyses for early progression, PFS, and OS identified elevated LDH and two or more extranodal sites at time of decision and the same predictors at time of treatment (i.e., increased CRP, two or more extranodal sites, and total metabolic tumor volume >80 mL), the authors noted.

Our risk model identifying early failure [risk factors] should assist in better selection of these patients for CAR T-cell therapy, the researchers concluded.

See more here:
These Factors Predict Early Progression Following CAR-T Therapy in DLBCL - DocWire News

The latest report on global Cell Therapy market is concentrating on the merchant territory, geographical expanse, product and service variations and potent strategies and functionalities that amount to massive growth in the foreseeable future. With thorough examination of chief players each of the companies is methodically estimated and measured with detailed reference of their SWOT performance. Each of the emphasized players has been carefully examined to infer the inferences of their growth rendering strategies and futuristic competences to ensure plentiful remunerative returns.

The study profiles and examines leading companies and other prominent companies operating in the Cell Therapy Market industry.

List of key players profiled in the report:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Request for Sample Copy of Report to get more information about the market @ https://www.adroitmarketresearch.com/contacts/request-sample/611?utm_source=AD

The Cell Therapy Market research study considers the present scenario of the Cell Therapy Market industry and its market dynamics for the period 20202026. The report covers both the demand and supply aspects of the market. Cell Therapy Market research report provides market sizing, share, forecast estimation & approach, Covid19 aftermath Analyst view, strategic analysis, revenue opportunities, industry trends, competition outlook, insights and growth relevancy mapping, growth drivers, and vendor analysis.

Cell Therapy Market reports under the Cell Therapy industry are supported by various macro and microeconomic factors impacting the industry. We browse through historical data and provide an overview of the emerging markets and the next big opportunities for investors within the niche market. After COVID pandemic, there are increasing demand from emerging countries provides a good business opportunity for companies to invest in coming years. Our reports are updated with changing industry regulatory policies and offer insight depending on clients requirement.

Market Segmentation

Besides including versatile details on ample growth opportunities, revenue predictions and market specific dimensions and sales volume, global Cell Therapy market report also includes actionable information on segment stratification and revenue generation potential of each of the segments in steering uninterrupted growth trail. The report houses specific details on product and application-based segmentation. Type and end-use specifications remain crucial market segments. End-use preferences and industry requirements remain critical in segment diversification. Each of the segments is meticulously assessed to understand market share, technological advancements, and regulatory alterations that influence segment diversification, followed by holistic growth.

Points Covered in the Report:

* The report presents a granular outlook of global Cell Therapy market, entailing crucial details in vendor landscape. Besides harping on core information pertaining to key market veterans.

* Elaborate details about these frontline market players, complete with assessment of their growth strategies, and positioning on the global growth curve have been intrinsically mentioned in the report.

* Actionable insights on other relevant market players active at the regional and local levels have also been discussed at length.

* Requisite information revealing details on product manufacturers, product innovations, application portfolios of all the major players have been etched in the report to inculcate growth proficient business decisions.

You can buy the complete report @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market?utm_source=AD

Cell Therapy Market Market Segmentation as per below:

Based on Product Types:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

Segmentation Overview:

Significant details comprising sales overview as well as revenue generation trends across specific geographical pockets have also been highlighted in the report.

IN terms of geographical diversification, global Cell Therapy market has an extended regional diaspora, that is widely spread across various growth-beds comprising North and South American nations, European countries as well as several other countries across MEA and APAC that demonstrate promising growth opportunities and pathbreaking avenues.

Our seasoned team of researchers have entailed diversified information mix about dominant industry trends, novel product portfolios, corporate activities as well as collaborations prevalent amongst players in the competitive isle.

Subsequent sections of the report reveal indispensable information on the competition intensity prevalent amongst various market players. A dedicated section on leading players and other aspiring market participants have all been highlighted at length.

Based on Market Segmentation, the report also sheds light on crucial market segments concerning product and service type, existing applications and scope for novelties in the application domain have also been widely discussed in this elaborate report.

Key Market Insights:

*The report provides the following insights into the Cell Therapy Market for the forecast period 20202026.

*Offers market sizing and growth prospects of the Cell Therapy Market for the forecast period 20202026.

*Provides comprehensive insights on the latest industry trends, market forecast, and growth drivers in the Cell Therapy Market.

*Includes a detailed analysis of market growth drivers, challenges, and investment opportunities.

*Delivers a complete overview of market segments and the regional outlook of the market.

*Offers an exhaustive summary of the vendor landscape, competitive analysis, and key market strategies to gain a competitive advantage in the Cell Therapy Market.

Know more COVID-19 Impact Analysis & Post Covid Opportunities @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611?utm_source=AD

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Continue reading here:
Cell Therapy Market Global Research Report Information by Product, by Distribution Channel, and by Region Forecast Till 2025 - Cheshire Media

The Global CAR-T Cell Therapy Market is anticipated to expand at a CAGR of around XX% during the forecast period, 20202026. Growing adoption of cloud-based solutions and rising need for amalgamating health records on a single platform is anticipated to boost the market CAR-T Cell Therapy growth. These are some of the major factors, which has an impact on the CAR-T Cell Therapy market. The use of technology has transformed the its uses in different sector. This drives the growth of CAR-T Cell Therapy market. Technology is used for the transformation of this sector, and to reduce the burden on employees.

List ofTop Key Playersof CAR-T Cell Therapy Market:Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Legend Biotech (Genscript Biotech Corporation), CARsgen Therapeutics, Ltd., Mustang Bio, Inc., Sorrento Therapeutics Inc.

Get Sample PDF Copy (includingCOVID19 Impact Analysis,full TOC, Tables, and Figures) of CAR-T Cell Therapy Market Report @ https://www.zealinsider.com/report/13766/car-t-cell-therapy-market#sample

CAR-T Cell Therapy is an advanced integrated information system for the management of all the aspects involved in operations such as financial, medical, administrative, legal, and compliance. These are some of the factors, which contribute to the CAR-T Cell Therapy market. The report on CAR-T Cell Therapy market also includes business intelligence, revenue cycle management, and electronic health records. Across the globe, various health organizations have installed CAR-T Cell Therapy software in order to streamline their business and operation process, better manage projects of all sizes, and boost their work efficiency across the management or board. These are some of the factors, which contribute to the growth of the CAR-T Cell Therapy market.

Market Trends, Drivers, Restraints, and Opportunities:

Increasing adoption of cloud-based solutions and integration of emerging technologies such as Artificial Intelligence (AI) and Machine Learning (ML) with hospital management solutions for data analysis is a major factor driving the growth of the CAR-T Cell Therapy market. Rising adoption of latest technologies such as online report generation that helps in cost cutting and improves the communication with patients is expected to boost the demand for an integrated software. This, in turn, is driving the growth for the CAR-T Cell Therapy market.

Growing demand for maintaining transparency across different departments and flexibility to access data at any time and from anywhere has increased the demand for innovative solutions and thus fueling the growth of the CAR-T Cell Therapy market. Shifting organizations preference from traditional ways of management, rising demand for automated systems and solutions, and streamlining all the aspects of business management is propelling the CAR-T Cell Therapy market growth.

Growing need to manage regulatory compliance through effective utilization of workforce management systems is propelling the market growth. Rising expenditure in the healthcare industry and government initiatives to upgrade healthcare facility infrastructure is fueling the CAR-T Cell Therapy market growth. Growing concerns for data security and high costs of deployment has been restraining the CAR-T Cell Therapy market growth.

Enquire before purchasing this report and For Best Discount @ https://www.zealinsider.com/report/13766/car-t-cell-therapy-market#inquiry

Key Businesses Segmentation of CAR-T Cell Therapy Market:

By Types, the CAR-T Cell Therapy Market can be Splits into:CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll

By Applications, the CAR-T Cell Therapy Market can be Splits into:Acute Lymphocytic, Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer

Why Choose Us:

We offer industry-leading critical reports with accurate insights into the future of the market. Our reports have been evaluated by some industry experts in the market, thus making them beneficial for the companys to maximize their return on investments. We provide a comprehensive pictorial representation of the information, strategic recommendations, outcomes of the analytical tools to offer an elaborate landscape, highlighting the key market players, and also provide SWOT analysis, product life cycle of the products. A detailed information of the external factors are covered on the PESTEL analysis. We also provide detailed information on COVID-19. This detailed assessment of the market will help the company increase efficiency of the CAR-T Cell Therapy market. The demand and supply dynamics offered in the report give a 360 degree view of the CAR-T Cell Therapy market.

Our report helps readers decipher the current and future constraints in the CAR-T Cell Therapy Market, and help them formulate optimum business strategies to maximize growth in the CAR-T Cell Therapy market.

Access Full Report, here: https://www.zealinsider.com/report/13766/car-t-cell-therapy-market

Originally posted here:
Impact of Covid-19 on CAR-T Cell Therapy Market 2020-2028 Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Legend Biotech...

FLORHAM PARK, N.J., Dec. 1, 2020 /PRNewswire/ -- Celularity announced today that the independent Data Monitoring Committee (DMC) completed the first assessment of the ongoing Phase I/II CYNK-001-COVID-19(CYNKCOVID) study (https://clinicaltrials.gov/ct2/show/NCT04365101) with CYNK-001 off-the-shelf, allogeneic, natural killer (NK) cell therapy in adults with COVID-19. The DMC confirmed the absence of dose-limiting toxicities and recommended to move forward with the trial. Additionally, there was no evidence of worsening of inflammatory biomarkers observed. The observed clinical findings justify the continuation of the trial. Enrollment is ongoing in this multi-center clinical study with active sites in Arizona, Arkansas, California, New Jersey, and Washington.

"We are encouraged that an esteemed group of independent experts in COVID-19 and cellular therapy determined that CYNK-001 was safe in the first participants receiving the treatment on the multi-site national study. Our goal now is to rapidly complete enrollment of the study so we can determine the efficacy of this promising treatment for COVID-19 with the epidemic resurging in the United States and few good treatment options for many patients,"said the national PI for the CYNKCOVID clinical trial, Corey Casper, M.D., M.P.H.

"The administration of NK cells may have the potential to both control viral infection while also coordinating a more effective immune response that could lead to strong and lasting protection against viruses. With the increasing incidence of COVID-19 nationwide, Celularity reaffirms our commitment to the development of CYNK-001 as a potential therapeutic treatment for patients with limited treatment options. Through our collaboration with investigators, we anticipate rapid enrollment culminating in the next DMC review of safety and efficacy data," said Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman and Chief Executive Officer.

The Phase I/II CYNK-001-COVID-19 (CYNKCOVID) clinical trial investigating CYNK-001 is continuing to enroll to the next evaluation milestone where the external, independent DMC will review the phase I data for both safety and efficacy. Celularity continues to accumulate safety data on CYNK-001 across a broad platform of programs including COVID-19, as well as hematologic and solid tumor malignancies.

About NK Cells NK cells are innate immune cells with an important role in early host response against various pathogens. Multiple NK cell receptors are involved in the recognition of infected cells. Studies in humans and mice have established that there is robust activation of NK cells during viral infection, regardless of the virus class, and that the depletion of NK cells aggravates viral pathogenesis.

About CYNK-001 CYNK-001 is an investigational cryopreserved allogeneic, off-the-shelf NK cell therapy developed from placental hematopoietic stem cells. CYNK-001 is being investigated as a potential treatment option in adults with COVID-19, as well as for various hematologic cancers and solid tumors. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity. CYNK-001 cells derived from the placenta are currently being investigated as a treatment for acute myeloid leukemia (AML), multiple myeloma (MM), and glioblastoma multiforme (GBM).

About Celularity Celularity, headquartered in Florham Park, N.J., is a next-generation Biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf allogeneic cellular therapies. Celularity's innovative approach to cell therapy harnesses the unique therapeutic potential locked within the cells of the post-partum placenta. Through nature's immunotherapy engine the placenta Celularity is leading the next evolution of cellular medicine with placental-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com

Media Contact Factory PR Email: [emailprotected]

SOURCE Celularity, Inc.

Read the original post:
Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 Study - PRNewswire

With the success of first vaccine to reach phase I clinical trial and turning out to be safe, well-tolerated, and capable of generating an immune response against the virus in humans, a lot of hope has been created with this vaccine. However, the research is still ongoing to develop novel therapeutic treatments that could aid infected patients in the meantime. One such growing area of interest is the use of cell therapy.

Cell Therapy: A Potential Treatment for COVID-19?

Cell therapies represent highly innovative therapeutic approaches that have revolutionized healthcare practices. Several studies from all over the world has proposed stem-cells based therapy, specifically mesenchymal stem cells, as a suitable remedial approach in the treatment of acute respiratory distress syndrome (ARDS), which is the leading cause of death in COVID-19 patients. Even though there are no approved cell therapy-based approaches for the prevention or treatment of COVID 19, however, many clinical trials have begun, and scientists are trying relentlessly to develop a therapeutic to treat this disease.

Companies Engaged in the Manufacturing of Cell Therapies

Presently, over 100 industry players and 60 non-industry players are involved in the manufacturing of cell therapies; of these, 52% have the required capabilities for manufacturing T-cell therapies.

The Key Hubs of Cell Therapy Manufacturing

Majority of the industrial stakeholders (41%) are based in North America, followed by those based in Europe (31%) and the remaining in Asia Pacific. It is worth mentioning that within Asia Pacific, Japan (8) emerged as a popular hub for cell therapy manufacturers.

Demand for Cell Therapies (in terms of number of patients) is Anticipated to Grow at a CAGR of >21%, During 2019-2030

Given that advanced therapeutic medicinal products (ATMPs) is relatively a niche domain, the overall commercial demand for cell therapies is estimated to be more than 18,500 patients in 2019 and this value is likely to grow to close to 0.4 billion patients by 2030.

To get a detailed information on the key players, recent developments, capacity available, demand and the likely market evolution, visit this link

Cell Therapy: A Potential Treatment for COVID-19?

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

See the rest here:
Cell Therapy: A Potential Treatment for COVID-19? | Roots Analysis - Cheshire Media

Treatment decisions in mantle cell lymphoma (MCL) have become more nuanced since the FDA approval of the CAR T-cell therapy brexucabtagene autoleucel (Tecartus) in the relapsed/refractory setting, explained Alan P. Z. Skarbnik, MD.

Previously, the treatment of choice for patients who recurred after high-dose therapy and transplant had been 1 of the 3 FDA-approved BTK inhibitors: ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa). Now, there is a decision-making process between BTK inhibitors and CAR T-cell therapy, which is driven by the time to relapse, disease burden, and overall performance status of the patient.

If a patient recurs 8 or 9 years after transplant and doesnt have a lot of disease, a BTK inhibitor may be a better choice at that point. That way, you can safeguard the risks of CAR T-cell therapy to a later time. I do have a number of patients who have very long remissions or disease control with BTK inhibitors in that setting, said Skarbnik. Patients who recur shortly after transplantation who have larger bulk of disease and are more symptomatic may be better candidates for CAR T-cell therapy.

In an interview with OncLive, Skarbnik, a hematologist/oncologist with Novant Health, discussed the data with available treatment options in relapsed/refractory MCL and shared some of the elements of treatment selection.

OncLive: How do you approach treatment selection among the 3 FDA-approved BTK inhibitors in MCL?

Skarbnik: We have not had a head-to-head comparison trial between the 3 agents. All 3 agents are available and efficacious. All we have are cross-trial comparisons. The duration of response [DOR] in the acalabrutinib trial seems to be longer. However, patients were in earlier lines of therapy; the median number of prior lines of therapy was 2 vs 3 in the ibrutinib trial. That may contribute to the difference in DOR. Zanubrutinib has a very good DOR and depth of response.

All 3 drugs seem to be safe and well tolerated. They have different safety profiles, which is not [to say that] one is better than the other, but [rather] that you have to determine what adverse effects [AEs] will be better tolerated in a particular patient.

There is head-to-head comparison between zanubrutinib and ibrutinib in Waldenstrm macroglobulinemia. In terms of the safety profile, zanubrutinib seems to be better tolerated in that particular trial and in that particular disease. You may extrapolate that to other disease settings, because the mechanism of action of the drugs is the same throughout. The newer second-generation BTK inhibitors may be better tolerated than the first-generation BTK inhibitor ibrutinib, but we cant say that yet with certainty. All 3 drugs are great. [The decision is going to come down to] physicians choice.

How has CAR T-cell therapy affected the paradigm?

Brexucabtagene autoleucel was recently approved in MCL based on data from the ZUMA-2 study, which evaluated this treatment in patients with recurrent, relapsed/refractory MCL who had been previously exposed to BTK inhibitor. However, the approval did not require patients to have been exposed to a BTK inhibitor in the commercial setting. Now, its approved for second-line or [later] use, which is appropriate at this point, because even though BTK inhibitors are a great treatment option for patients with relapsed MCL, the best DOR we have seen so far is close to 26 months, which certainly is not ideal.

We try to treat MCL more aggressively in the frontline setting with high-dose cytarabine-containing induction regimens followed by high-dose chemotherapy and autologous stem cell transplant or rescue. This seems to give patients a longer remission and progression-free survival than other treatment approaches in the frontline setting.

The biggest concern here is for patients who recur shortly after that intensive therapythose with recurrent disease 1 to 3 years after a stem cell transplant. These patients have a higher risk of resistance to second-line therapy, and are at a higher risk of early progression after second-line therapy. The treatment of choice up until now has been BTK inhibitors, which are easy to take and are readily available. The AEs are well tolerated, and [patients] do have a response [to this type of treatment].

The length of response is the issue here. We now have the option of CAR T-cell therapy in that setting. Again, that is going to depend on how soon the patient relapses after transplant and their disease burden. We also have to consider the overall performance status of the patient. Are they going to be a good candidate to withstand the AEs of CAR T-cell therapy, or are they a better candidate for a BTK inhibitor?

We dont have long-term follow-up for the [ZUMA-2] trial yet. The true, long-term effect of CAR T-cell therapy in terms of efficacy and disease is not known yet. We dont know if using CAR T-cell therapy prior to a BTK inhibitor changes the response rate or DOR. We dont have those data. It is something well have to look back at retrospectively and try to compare as best as we can.

Certainly, I would be more inclined to use CAR T-cell therapy in a younger patient who has early recurrence after frontline induction, especially if they undergo transplant, and certainly for those who recur after BTK inhibitors. Very few agents can salvage a patient [after that]. In terms of chemotherapy, [rituximab/bendamustine with low-dose cytarabine] seems to be the chemotherapy regimen that has better response rates in the BTK inhibitorrefractory or relapsed setting. However, CAR T-cell therapy was studied specifically in that setting, so its a good option for those patients.

Original post:
CAR T-Cell Therapy Creates Opportunities for Individualized Treatment in MCL - OncLive